Kuros Biosciences (KURN) H2 2024 earnings summary

Executive summary

• Achieved record revenue growth in 2024, with MagnetOs sales surging 136% and total Medical Device sales reaching CHF 75.6 million, supported by strategic expansion in U.S. and international markets and a five-year Medtronic partnership.

• Expanded regulatory clearances and commercial presence to over 20 countries, increasing the global addressable market and hospital penetration by 85% year-over-year.

• Achieved positive adjusted EBITDA of CHF 9.0 million (11.9% margin), marking a turnaround from prior losses and reaching profitability from continuing operations.

• Discontinued Fibrin-PTH operations after interim analysis favored MagnetOs, eliminating a cost center and aligning G&A with sales volume.

• Digitization, operational efficiency, and a robust product pipeline set the groundwork for continued scalable growth.

Financial highlights

• Medical Device sales increased 125% to CHF 75.6 million, with gross profit rising to CHF 62.0 million and adjusted EBITDA margin at 11.9%.

• Operating cash flow was positive, with cash and equivalents at CHF 18.0 million at year-end, bolstered by CHF 3.8 million from LTI exercises.

• Net loss narrowed to CHF 4.3 million, and operating loss reduced to CHF 5.0 million.

• Revenue and volume grew ~450% from 2022 to 2024, while fixed costs grew ~100%.

• No debt and strong cash position support organic and selective inorganic growth.

Outlook and guidance

• Expects at least 60% revenue growth in 2025, targeting USD 120 million in sales, and projects USD 220–250 million in revenue by 2027.

• Plans to change reporting currency from CHF to USD in 2025 to align with revenue base and investor expectations.

• Sufficiently financed for planned organic growth, with continued expansion into new markets and product segments.

• Focus remains on organic growth, with potential for opportunistic inorganic expansion and selective acquisitions.